logo

For the Inventor, By the Inventor

Rockville, MD, United States of America

Rexahn Pharmaceuticals, Inc.


USPTO Granted Patents = 19

% Expired Patents = 63.2



Forward Citations = 40

Loading Chart...
Loading Chart...

26 inventors (with patents filed for the assignee):

goldMedal Young Bok Lee (16 out of 20 patents)

silverMedal Deog Joong Kim (13 out of 15 patents)

bronzeMedal Chang Ho Ahn (7 out of 11 patents)

4.  Chang-Ho Ahn (5 out of 6 patents)

5.  Reza Mazhari (4 out of 8 patents)

6.  Yi Wang (3 out of 7 patents)

7.  Haifeng Yin (3 out of 3 patents)

8.  Eliezer Falb (3 out of 4 patents)

9.  Leigh Andre Pearcey (3 out of 3 patents)

10.  Jonathan Cummins (3 out of 4 patents)

11.  Petra Dieterich (3 out of 6 patents)

12.  Jean-Francois Carniaux (3 out of 5 patents)

13.  Vikram Chandrakant Purohit (3 out of 3 patents)

14.  Daniel Edward Emrich (2 out of 2 patents)

15.  Godefridus J Peters (2 out of 2 patents)


19 patents:

1. 10570101 - Quinoxalinyl-piperazinamide methods of use (2020-02-25),
2. 10278971 - Fluorocyclopentenylcytosine methods of use (2019-05-07),
3. 10052321 - Nanoparticulate compositions and formulations of piperazine compounds (2018-08-21),
4. 9969698 - Quinoxalinyl-piperazinamide methods of use (2018-05-15),
5. 9920016 - Process for the preparation of 4-amino 1-((1S,4R,5S)-2-fluoro-4,5-dihydroxy-3-hydroxymethyl-cyclopent-2-enyl)-1H-pyrimidin-2-one (2018-03-20),
6. 9782410 - Fluorocyclopentenylcytosine methods of use (2017-10-10),
7. 9744167 - Nanoparticulate compositions and formulations of piperazine compounds (2017-08-29),
8. 9713615 - Tetrahydroisoquinolin-2-yl-(quinazolin-4-yl)methanone compounds (2017-07-25),
9. 9533958 - Process or the preparation of 4-amino 1-((1S,4R,5S)-2-fluoro-4,5-dihydroxy-3-hydroxymethyl-cyclopent-2-Enyl)-1H-pyrimidin-2-one (2017-01-03),
10. 9434610 - HPMA—docetaxel conjugates and uses therefore (2016-09-06),
11. 9193707 - Tetrahydroisoquinolin-2-yl-(quinazolin-4-yl)methanone compounds (2015-11-24),
12. 9150520 - Process for the preparation of 4-amino-1-((1S,4R,5S)-2-fluoro-4,5-dihydroxy-3-hydroxymethyl-cyclopent-2-enyl)-1H-pyrimidin-2-one (2015-10-06),
13. 8846110 - Polymeric systems for the delivery of anticancer drugs (2014-09-30),
14. 8598173 - 1-[(6,7-substituted alkoxyquinoxalinyl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives for treating tumors (2013-12-03),
15. 8404698 - Quinazoline derivatives and therapeutic use thereof (2013-03-26),
Company Overview
Rexahn Pharmaceuticals, Inc. is a biopharmaceutical company based in Rockville, Maryland, focused on the development of innovative therapies for the treatment of cancer and central nervous system disorders. The company specializes in advancing novel drug candidates through its proprietary technology platforms, which include targeted therapeutics and biologics. Rexahn aims to address unmet medical needs by leveraging its expertise in drug discovery and development, contributing to the advancement of healthcare solutions.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

19 Patents

#37 in Rockville, MD

#232 in Maryland

#17,123 in US

#32,623 in the World

Rockville, MD (US)
Rockville, MD, United States of America

Rexahn Pharmaceuticals, Inc.

Forward Citations = 40

26 inventors:

goldMedal Young Bok Lee (16 out of 20 patents)

silverMedal Deog Joong Kim (13 out of 15 patents)

bronzeMedal Chang Ho Ahn (7 out of 11 patents)

4.  Chang-Ho Ahn (5 out of 6 patents)

5.  Reza Mazhari (4 out of 8 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Rexahn Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/rexahn-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…